FindTrial
Sign In

Cabozantinib 40 MG

DRUG4 trials

Sponsors

Patrick Joseph Loehrer Sr., University of Bologna, Grupo Espanol de Tumores Neuroendocrinos, National Taiwan University Hospital

Conditions

AdenocarcinomaAnaplastic Thyroid CancerEsophageal CancerMetastatic CancerNeuroendocrine TumorNon Small Cell Lung CancerPancreatic Adenocarcinoma MetastaticParaganglioma

Phase 2

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
TerminatedNCT03213626
Patrick Joseph Loehrer Sr.Pancreatic Adenocarcinoma Metastatic
Start: 2017-10-13End: 2019-11-18Updated: 2020-08-27
Phase II Study With Cabozantinib in Patients With RET Positive NSCLC
NCT04131543
University of BolognaNon Small Cell Lung Cancer
Start: 2019-08-07End: 2022-08-07Target: 25Updated: 2019-10-18
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
CompletedNCT04400474
Grupo Espanol de Tumores NeuroendocrinosAdenocarcinoma, Anaplastic Thyroid Cancer, Neuroendocrine Tumor +2
Start: 2020-10-07End: 2023-12-15Updated: 2025-06-19
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
CompletedNCT05007613
National Taiwan University HospitalEsophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma
Start: 2021-06-23End: 2024-12-01Updated: 2025-01-01

Related Papers

Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.
Journal of Clinical Oncology2024-06-01
Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
Journal of Clinical Oncology2024-02-017 citations
A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.
Journal of Clinical Oncology2022-01-19
A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma (PDAC).
Journal of Clinical Oncology2020-05-205 citations
A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.
Journal of Clinical Oncology2018-05-20